Mei-Chuan Ko

Mei-Chuan Ko

Auto-generated profile, based on publicly available information

Mei-Chuan Ko

Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
CDChristopher R. Donnelly
Christopher R. Donnelly
CJChangyu Jiang
Changyu Jiang
AAAmanda S. Andriessen
Amanda S. Andriessen
KWKaiyuan Wang
Kaiyuan Wang
ZWZilong Wang
Zilong Wang
RJRu-Rong Ji
Ru-Rong Ji

19 August 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FZFang Zheng
Fang Zheng
WYWenchao Yang
Wenchao Yang
MKMei-Chuan Ko
Mei-Chuan Ko
JLJunjun Liu
Junjun Liu
HCHoon Cho
Hoon Cho
CZChang-Guo Zhan
Chang-Guo Zhan

29 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HDHuiping Ding
Huiping Ding
NKNorikazu Kiguchi
Norikazu Kiguchi
DYDennis Yasuda
Dennis Yasuda
PDPankaj R. Daga
Pankaj R. Daga
WPWillma E. Polgar
Willma E. Polgar
MKMei-Chuan Ko
Mei-Chuan Ko
The small-molecule AT-121 is an agonist of nociceptin and mu opioid peptide receptors and mediates analgesia without opioid-associated side effects in nonhuman primates.

25 April 2014 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
WSW Schröder
W Schröder
DLD G Lambert
D G Lambert
MKM C Ko
M C Ko
TKT Koch
T Koch
Despite high sequence similarity betweenNOP(nociceptin/orphaninFQopioid peptide) and opioid receptors, marked differences in endogenous ligand selectivity, signal transduction, phosphorylation, desensitization, internalization and trafficking have been identified; underscoring the evolutionary difference betweenNOPand opioid receptors. Activation ofNOPreceptors affects nociceptive transmission in a site‐specific manner, with antinociceptive effects prevailing after peripheral and spinal activation, and pronociceptive effects after supraspinal activation in rodents. The net effect of systemically administeredNOPreceptor agonists on nociception is proposed to depend on the relative contribution of peripheral, spinal and supraspinal activation, and this may depend on experimental conditions. Functional expression and regulation ofNOPreceptors at peripheral and central sites of the nociceptive pathway exhibits a high degree of plasticity under conditions of neuropathic and inflammatory pain. In rodents, systemically administeredNOPreceptor agonists exerted antihypersensitive effects in models of neuropathic and inflammatory pain. However, they were largely ineffective in acute pain while concomitantly evoking severe motor side effects. In contrast, systemic administration ofNOPreceptor agonists to non‐human primates (NHPs) exerted potent and efficacious antinociception in the absence of motor and sedative side effects. The reason for this species difference with respect to antinociceptive efficacy and tolerability is not clear. Moreover, co‐activation ofNOPand μ‐opioid peptide (MOP) receptors synergistically produced antinociception inNHPs. Hence, both selectiveNOPreceptor as well asNOP/MOPreceptor agonists may hold potential for clinical use as analgesics effective in conditions of acute and chronic pain.

1 July 2004 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MKM. C. H. Ko
M. C. H. Ko
MSM. S. Song
M. S. Song
TET. Edwards
T. Edwards
HLH. Lee
H. Lee
NNN. N. Naughton
N. N. Naughton
Pruritus (itch sensation) is a significant clinical problem. The aim of this study was to elucidate the roles of opioid receptor types and the site of action in opioid-induced itch in monkeys. Observers who were blinded to the conditions counted scratching after administration of various drugs. Intravenous (i.v.) administration of μ opioid receptor (MOR) agonists (fentanyl, alfentanil, remifentanil, and morphine) evoked scratching in a dose- and time-dependent manner. However, the κ opioid agonist U-50488H [trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]-cyclohexyl)-benzeneacetamide] and δ opioid agonist SNC80 [(+)-4-[(αR)-α-[2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-N,N-diethylbenzamide] did not increase scratching. Intrathecal (i.t.) administration of peptidic MOR agonist [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO, 0.00032–0.01 mg) evoked scratching, but i.v. DAMGO (0.01–1 mg/kg) did not increase scratching. A similar difference between i.t. and i.v. effectiveness was seen with morphine. Antagonist studies revealed that i.v. administration of an opioid receptor antagonist (naltrexone, 0.0032–0.1 mg/kg) dose dependently attenuated scratching induced by i.v. fentanyl (0.018 mg/kg) or morphine (1 mg/kg). However, a peripherally selective opioid antagonist (quaternary naltrexone, 0.0032–0.32 mg/kg) did not block i.v. fentanyl- or morphine-induced scratching. Moreover, a histamine antagonist (diphenhydramine, 0.1–10 mg/kg), failed to attenuate scratching induced by i.t. morphine (0.032 mg) or i.v. morphine (1 mg/kg). Pretreatment with a selective MOR antagonist (clocinnamox, 0.1 mg/kg), but not κ or δ opioid antagonists (nor-binaltorphimine or naltrindole), blocked i.t. morphine-induced scratching. Together, these data suggest that MOR, not other opioid receptor types or histamine, mediates scratching evoked by opioid analgesics. More important, this study provides in vivo pharmacological evidence that activation of central MOR plays an important role in opioid-induced itch in primates.

1 April 2020 in Cell Reports
Verified
Journal Article
Open access
SMSantosh Mishra
Santosh Mishra
JWJoshua J. Wheeler
Joshua J. Wheeler
SPSaumitra Pitake
Saumitra Pitake
HDHuiping Ding
Huiping Ding
CJChangyu Jiang
Changyu Jiang
Thierry OlivryThierry Olivry
Thierry Olivry
Chronic allergic itch is a common symptom affecting millions of people and animals, but its pathogenesis is not fully explained. Herein, we show that periostin, abundantly expressed in the skin of patients with atopic dermatitis (AD), induces itch in mice, dogs, and monkeys. We identify the integrin αVβ3 expressed on a subset of sensory neurons as the periostin receptor. Using pharmacological and genetic approaches, we inhibited the function of neuronal integrin αVβ3, which significantly reduces periostin-induced itch in mice. Furthermore, we show that the cytokine TSLP, the application of AD-causing MC903 (calcipotriol), and house dust mites all induce periostin secretion. Finally, we establish that the JAK/STAT pathway is a key regulator of periostin secretion in keratinocytes. Altogether, our results identify a TSLP-periostin reciprocal activation loop that links the skin to the spinal cord via peripheral sensory neurons, and we characterize the non-canonical functional role of an integrin in itch.